Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
Radioligand therapy (RLT) is emerging as an essential pillar in cancer care. It is a targeted treatment approach that has shown clinical benefits in treating gastroenteropancreatic neuroendocrine tumors and advanced prostate cancer. It is also being researched as a promising treatment modality for several other advanced cancers. The scientific innovation in radioligand therapies is progressing rapidly; however, the healthcare system readiness for this treatment modality is lagging. There is a critical and urgent need to enhance the understanding of the current level of readiness for RLT across countries and to address issues impacting this in order to ensure patient access in a timely and equitable manner.
This report aims to further the discussion around RLT readiness in Europe by establishing key levers that should be tracked to assess overall capacity for this treatment. It also provides an initial set of data for these levers for four countries in Europe (France, Germany, Italy and Spain) to highlight the variation in identified capacity across countries and establish benchmarks that can be regularly assessed to prepare for the anticipated increase in radioligand therapy use.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.